Orthobiologics Market Growth, Share, Trends & Forecast 2024-2032 from Rohit Pujari's blog

IMARC Group’s report titled “Orthobiologics Market Report by Product (Demineralized Bone Matrix, Allograft, Bone Morphogenetic Protein, Viscosupplementation Products, Synthetic Bone Substitutes, and Others), Type (Knee, Ankle, Hip, Wrist and Shoulder, Spine, and Others), Application (Osteoarthritis and Degenerative Arthritis, Spinal Fusion, Fracture Recovery, Soft Tissue Injuries, Maxillofacial and Dental Applications), End User (Hospitals and Ambulatory Centers, Research and Academic Institutes, Dental Clinics and Facilities, Orthopedic Clinics), and Region 2024-2032”, The global orthobiologics market size reached US$ 6.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.1 Billion by 2032, exhibiting a growth rate (CAGR) of 4.5% during 2024-2032.

Grab a sample PDF of this report: https://www.imarcgroup.com/orthobiologics-market/requestsample

Factors Affecting the Growth of the Orthobiologics Industry:

• Rising Demand for Sports Medicine and Enhanced Recovery:

The rising participation in sports and physical activities is leading to an increase in sports-related injuries, thereby catalyzing the demand for rapid and effective recovery solutions. Orthobiologics, such as platelet-rich plasma (PRP) and stem cell therapy, are gaining popularity in sports medicine for their ability to accelerate the healing of injured tissues, reduce inflammation, and improve recovery outcomes. Athletes and active individuals often seek treatments that allow a quicker return to activity, making orthobiologics an attractive option. This focus on enhanced recovery and performance in sports medicine contributes significantly to the growth of the orthobiologics market.

• Advancements in Biotechnology and Regenerative Medicine:

Innovations in biotechnology and regenerative medicine are impelling the market growth. Advancements in stem cell research, gene therapy, and tissue engineering are leading to the development of more effective and diverse orthobiologic products. These innovations enable the creation of treatments that promote faster healing, reduce recovery times, and offer alternatives to traditional surgical methods. Continuous research and development (R&D) in this field expands the potential applications of orthobiologics, ranging from enhancing bone and tissue regeneration to treating complex injuries and degenerative conditions. This progress not only improves patient outcomes but also broadens the market's scope and appeal.

• Increasing Adoption of Minimally Invasive (MI) Procedures:

Rising preferences for MI surgical procedures among the masses across the globe are catalyzing the demand for orthobiologics. These procedures are favored for their benefits, including reduced pain, shorter hospital stays, and quicker recovery times. Orthobiologics, such as bone grafts, are used to promote tissue regeneration and improve surgical outcomes in orthopedic surgeries like spinal fusion, joint reconstruction, and fracture repair. This trend towards less invasive approaches aligns with patient preferences and healthcare objectives, which is propelling the market growth.

We explore the factors propelling the Orthobiologics Market growth, including technological advancements, consumer behaviors, and regulatory changes.

Leading Companies Operating in the Global Orthobiologics Industry:

• Arthrex Inc
• Globus Medical Inc.
• Integra LifeSciences
• Johnson & Johnson
• Medline Industries Inc.
• Medtronic plc
• NuVasive Inc
• Orthofix Medical Inc.
• Smith & Nephew plc
• Stryker Corporation
• Terumo Corporation
• Wright Medical Group N.V.
• Zimmer Biomet

Orthobiologics Market Report Segmentation:

By Product:

• Demineralized Bone Matrix
• Allograft
• Bone Morphogenetic Protein
• Viscosupplementation Products
• Synthetic Bone Substitutes
• Others

Viscosupplementation products represent the largest segment as it helps in restoring the viscoelastic properties of synovial fluid and reducing pain.

By Type:

• Knee
• Ankle
• Hip
• Wrist and Shoulder
• Spine
• Others

Knee holds the biggest market share due to the rising prevalence of knee osteoarthritis.   

By Application:

• Osteoarthritis and Degenerative Arthritis
• Spinal Fusion
• Fracture Recovery
• Soft Tissue Injuries
• Maxillofacial and Dental Applications

Osteoarthritis and degenerative arthritis account for the largest market share, driven by the increasing shift towards non-surgical and MI treatments.  

By End User:

• Hospitals and Ambulatory Centers
• Research and Academic Institutes
• Dental Clinics and Facilities
• Orthopedic Clinics

Hospitals and ambulatory centers exhibit a clear dominance in the market on account of their ability to offer comprehensive care and advanced medical facilities.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America enjoys a leading position in the orthobiologics market, which can be attributed to the presence of high-quality healthcare infrastructure.  

Global Orthobiologics Market Trends:

The rising prevalence of musculoskeletal disorders, such as osteoarthritis, rheumatoid arthritis, and osteoporosis, is supporting the market growth. Orthobiologics, which include bone grafts, stem cell therapy, and platelet-rich plasma (PRP), are increasingly utilized to enhance the body's natural healing processes. Patients and healthcare providers are preferring orthobiologics for their potential to reduce recovery time and improve outcomes without the need for invasive surgery. The increasing awareness among individuals about early diagnosis of musculoskeletal disorders is catalyzing the demand for orthobiologic products.

Furthermore, orthobiologics play a crucial role in facilitating these outpatient procedures by providing effective treatment options that do not require extended hospital stays. Treatments, such as PRP injections and MI stem cell therapies, can be performed in an outpatient setting, leading to faster recovery times and reduced healthcare costs.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
 Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1–631–791–1145